Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Sponsor Directory

Yale University clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 8:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1897
Shown on this page
12
Current sort
Recently updated
Sponsor scope
Yale University
Additional filters apply within this sponsor.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this sponsor

These controls apply only within Yale University. Default order is Recently updated. Add condition, therapy, location, or recruitment status to narrow this sponsor page further.

Reset sponsor filters
Clear filters
Showing 133–144 of 1,897 matching trials for sponsor Yale University.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Recruiting Phase 1 Interventional

Influence of Mavoglurant on Alcohol Craving and Drinking in Heavy Drinkers

NCT06136195
View directory record Official record
Conditions
Alcohol Consumption, Heavy Drinker, Alcohol Use Disorder (AUD)
Interventions
Mavoglurant
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 50 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 18, 2026, 8:26 PM EDT
Recruiting No phase listed Observational

Prospective Case Series Evaluating 6-Month and 12-Month Outcomes After Cryoneurolysis for Chronic Pain

NCT07639060
View directory record Official record
Conditions
Chronic Pain, PERIPHERAL NEUROPATHY, Occipital Neuralgia, Chronic Hip Pain, Hip Osteoarthritis, Knee Osteoarthritis, Spasticity, Chronic Low Back Pain, Lumbar Spondylosis, Cervical Spondylosis, Shoulder Arthritis, Causalgia, Chronic Pain Syndrome, Chronic Neck Pain
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Old Saybrook, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 18, 2026, 8:26 PM EDT
Active, not recruiting Phase 2 Interventional

The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer

NCT04699123
View directory record Official record
Conditions
Advanced Non-small Cell Lung Cancer
Interventions
NC318 800 mg, NC318 400 mg, Pembrolizumab
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 18, 2026, 8:26 PM EDT
Completed Not applicable Interventional

Song-making In a Group (SING)

NCT05929352
View directory record Official record
Conditions
Schizophrenia
Interventions
Musical Intervention
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 18, 2026, 8:26 PM EDT
Completed Phase 1 Interventional

Greater Occipital Nerve Blockade in Veterans With Post-concussion Headache: Sub-study 1

NCT06069791
View directory record Official record
Conditions
Post-Traumatic Headache
Interventions
Bupivacaine Injection
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 18, 2026, 8:26 PM EDT
Recruiting No phase listed Observational

Validation of Early Prognostic Data for Recovery Outcome After Stroke for Future, Higher Yield Trials

NCT05338697
View directory record Official record
Conditions
Stroke, Stroke, Acute, Stroke, Ischemic
Interventions
Transcranial Magnetic Stimulation (TMS)
Diagnostic Test
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
657 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
45
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 18, 2026, 8:26 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Evaluation of [18F]GATT-44 for Positron Emission Tomography Imaging of the GABA Transporter-1

NCT07457736
View directory record Official record
Conditions
Healthy Adult Participants
Interventions
[ 18F]GATT-44
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 18, 2026, 8:26 PM EDT
Recruiting Not applicable Interventional

Evaluation of the Clinical and Psychological Impact of Vitamin D Replacement in Adolescent Females at Risk for Polycystic Ovarian Syndrome (PCOS)

NCT04355572
View directory record Official record
Conditions
Polycystic Ovarian Syndrome in Adolescent Females, Vitamin D Deficiency
Interventions
Vitamin D 4000IU daily, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
13 Years to 21 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 18, 2026, 8:26 PM EDT
Active, not recruiting Phase 3 Interventional

FRIEND: Fibroids and Unexplained Infertility Treatment With Epigallocatechin Gallate; A Natural CompounD in Green Tea

NCT05364008
View directory record Official record
Conditions
Leiomyoma, Uterine
Interventions
Green Tea Extract, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
4
States / cities
New Haven, Connecticut • Chicago, Illinois • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 18, 2026, 8:26 PM EDT
Not yet recruiting Not applicable Interventional

Virtual Tai Chi for Chronic Low Back Pain (Spine 2027)

NCT07772154
View directory record Official record
Conditions
Low Back Pain, Chronic Low-back Pain (cLBP)
Interventions
Virtually Delivered Integrated Tai Chi, Qigong, and Meditation (VDTQM)
Behavioral
Lead sponsor
New York Medical College
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 18, 2026, 8:26 PM EDT
Not yet recruiting Phase 1 Interventional

Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes

NCT07772960
View directory record Official record
Conditions
Alcohol Use Disorder (AUD), Obesity (BMI Equal to or >30)
Interventions
Placebo, Semaglutide 1.0 mg, Semaglutide 2.0 mg
Other · Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 68 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 18, 2026, 8:26 PM EDT
Not yet recruiting Phase 3 Interventional

COMparison Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE"

NCT07281027
View directory record Official record
Conditions
New Onset Refractory Status Epilepticus, New-Onset Refractory Status Epilepticus, Febrile Infection-Related Epilepsy Syndrome (FIRES)
Interventions
Anakinra, Tocilizumab, Standard medical treatment
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
2 Years and older
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
25
States / cities
Phoenix, Arizona • Aurora, Colorado • New Haven, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 18, 2026, 8:26 PM EDT

About this Yale University sponsor directory page

What this page lists
U.S. ClinicalTrials.gov public records where Yale University is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results
Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Yale University trials.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

Related: all sponsor pages, browse by condition, browse by drug or therapy, browse by U.S. city, trials at Yale in New Haven, CT, or open the full search for Yale University.